The protein determinants for RNA packaging in avian sarcoma and leukemia virus. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The protein determinants for RNA packaging in avian sarcoma and leukemia virus.

Diss Abstr Int [B]; 54(12):6066 1994. Unique Identifier : AIDSLINE ICDB/95607125
Sakalian M; Cornell Univ.


Abstract: In all retrovirus systems studied, the leader region of the RNA contains a cis-acting sequence called Psi that is required for packaging the viral RNA genome. Since the pol and env genes are dispensable for formation of RNA-containing particles, the gag gene product must have an RNA binding domain(s) capable of recognizing Psi. The nucleocapsid protein (NC) of avian sarcoma and leukemia viruses (ASLV) is found tightly associated with genomic RNA in virions. I examined the binding properties of the ASLV NC protein in a gel mobility-shift assay. NC binding to RNA produced a high molecular weight complex that could be progressively increased in size by further addition of NC. In agreement with previous reports, the NC-RNA interaction was nonspecific. Comparison of the gel mobility-shift with filter-binding showed that filter-binding is not a valid assay for NC-RNA interaction. NC is initially produced as a part of the Gag polyprotein precursor and is not released in its mature form until after virus assembly and proteolytic maturation. To gain information about which portion(s) of Gag, in addition to NC, are required for RNA packaging in the ASLV, I examined a series of partial gag deletion mutants that still can lead to assembly of virus-like particles. The incorporation of RNA into these particles was assayed by RNase protection. The efficiency of packaging was determined by normalization of the amount of Psi+ RNA to the amount of Gag protein released in virus-like particles. Specificity of packaging was determined by comparisons of Psi+ and Psi- RNA in particles and in cells. The results indicate that much of Gag is unnecessary for both efficient and specific packaging. Deletions within the NC domain reduced both the efficiency and specificity of packaging or eliminated it entirely. Among mutants that retained the ability to package, a deletion within the CA domain (which includes the Major Homology Region) was the least efficient. I also examined particles of the packaging mutant SE21Q1b. The data suggest that the random RNA packaging behavior of this mutant is not due to a specific defect but rather results from the cumulative effect of point mutations throughout the gag gene. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD94-16737)
Keywords: Animal Birds Capsid/*GENETICS Gene Products, gag/GENETICS Genes, env Genes, pol Genome, Viral Leukemia/*VIROLOGY RNA, Viral/*GENETICS Sarcoma Viruses, Avian/*GENETICS Sequence Deletion Viral Core Proteins/*GENETICS THESISKWDanimalbirdscapsid/KWDgeneticsgeneproducts,gag/geneticsgenes,envgenes,polgenome,viralleukemia/KWDvirologyrna,viral/KWDgeneticssarcomaviruses,avian/KWDgeneticssequencedeletionviralcoreproteins/KWDgeneticsthesis
950430
M9541139

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .